STTR Phase I: A platform to overcome immunodominance in vaccine development — NSF Award to NITRO BIOSCIENCES INC. (DE, $304,438)
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to advance a novel vaccine platform to develop engineered vaccines that provide longer lasting protection against infectious diseases. Several current vaccines face challenges in reliably protecting populations
| Award title | STTR Phase I: A platform to overcome immunodominance in vaccine development |
|---|---|
| Award ID | 2507491 |
| Awardee | NITRO BIOSCIENCES INC. |
| City | NEWARK |
| State | DE |
| Amount obligated | $304,438 |
| Principal investigator | Neil Butler |
| Program | STTR Phase I |
| Start date | 10/01/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to advance a novel vaccine platform to develop engineered vaccines that provide longer lasting protection against infectious diseases. Several current vaccines face challenges in reliably protecting populations against rapidly evolving pathogens where prior exposure negatively impacts vaccine effectiveness. This project develops an innovative approach aimed at boosting the immune response |
| Source | NSF Awards |
$799/mo
Try NSFGrants →